Found: 7
Select item for more details and to access through your institution.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 12, p. 1, doi. 10.1007/s11095-020-02933-6
- By:
- Publication type:
- Article
A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E175, doi. 10.1002/ajh.26136
- By:
- Publication type:
- Article
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 01, doi. 10.3389/fimmu.2023.1119510
- By:
- Publication type:
- Article
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 1, p. 48, doi. 10.1002/psp4.12482
- By:
- Publication type:
- Article
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
- Published in:
- 2017
- By:
- Publication type:
- journal article